Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TSPO | P30536 | 1/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | PER2 | O15055 | 1/20 | 0.30 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.30 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | IL1R1 | P14778 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13486068 | 1.00 | KDM4E (0.38) | KDM4EATML3MBTL1TSPOPTGER4 | |
| SCHEMBL13486069 | 1.00 | KDM4E (0.38) | KDM4EATML3MBTL1TSPOPTGER4 | |
| SCHEMBL13485981 | 1.00 | KDM4E (0.38) | KDM4EATML3MBTL1TSPOPTGER4 | |
| SCHEMBL13486076 | 1.00 | KDM4E (0.38) | KDM4EATML3MBTL1TSPOPTGER4 | |
| SCHEMBL13485971 | 1.00 | KDM4E (0.38) | KDM4EATML3MBTL1TSPOPTGER4 | |
| SCHEMBL13486072 | 0.99 | KDM4E (0.38) | KDM4EATML3MBTL1TSPOPTGER4 | |
| SCHEMBL13485985 | 0.99 | KDM4E (0.38) | KDM4EATML3MBTL1TSPOPTGER4 | |
| SCHEMBL13485845 | 0.99 | KDM4E (0.38) | KDM4EATML3MBTL1TSPOPTGER4 | |
| SCHEMBL13486023 | 0.99 | KDM4E (0.38) | KDM4EATML3MBTL1TSPOPTGER4 | |
| SCHEMBL13724744 | 0.98 | KDM4E (0.40) | KDM4EATML3MBTL1PTGER4RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8298684-B2 | Phenylcarbazole compounds, organic light emitting device comprising the phenylcarbazole compounds and flat panel display device comprising the organic light emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2012-10-30 | — | — | US | disclosed |
| US-8298684-B2 | Phenylcarbazole compounds, organic light emitting device comprising the phenylcarbazole compounds and flat panel display device comprising the organic light emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2012-10-30 | — | — | US | disclosed |
| US-20100032656-A1 | Phenylcarbazole compounds, organic light emitting device comprising the phenylcarbazole compounds and flat panel display device comprising the organic light emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2010-02-11 | — | — | US | disclosed |
| US-20100032656-A1 | Phenylcarbazole compounds, organic light emitting device comprising the phenylcarbazole compounds and flat panel display device comprising the organic light emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100032656-A1 | Phenylcarbazole compounds, organic light emitting device comprising the phenylcarbazole compounds and flat panel display device comprising the organic light emitting device | OCIAD1, OXA1L, MAP1LC3B | KDM4E 3067/4885ATM 3948/4885L3MBTL1 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.